The presentation of stellar full results for its nano-engineered Vyxeos at the American Society of Clinical Oncology meeting has been the icing on the cake for Celator Pharmaceuticals Inc., which has had a rapid rise in the past few months, culminating in its acquisition by Jazz Pharmaceuticals PLC just ahead of the cancer conference.
Jazz swooped in on May 31 with a cash offer of $30.25 per share – a huge increase over where...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)